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Abstract
Background: Bone metastases are frequent complications of breast cancer. Recent literature implicates multiple chemokines
in the formation of bone metastases in breast cancer. However, the molecular mechanism of metastatic bone disease in breast
cancer remains unknown. We have recently made the novel observation of the BST2 protein expression in human breast cancer
cell lines. The purpose of our present study is to investigate the expression and the role of BST2 in bone metastatic breast
cancer.
Methods: cDNA microarray analysis was used to compare the BST2 gene expression between a metastatic to bone human
breast cancer cell line (MDA-231BO) and a primary human breast cancer cell line (MDA-231). The BST2 expression in one bone
metastatic breast cancer and seven non-bone metastatic breast cancer cell lines were also determined using real-time RT-PCR
and Western blot assays. We then employed tissue array to further study the BST2 expression in human breast cancer using
array slides containing 20 independent breast cancer tumors that formed metastatic bone lesions, 30 non-metastasis-forming
breast cancer tumors, and 8 normal breast tissues. In order to test the feasibility of utilizing BST2 as a serum marker for the
presence of bone metastasis in breast cancer, we had measured the BST2 expression levels in human serums by using ELISA on
43 breast cancer patients with bone metastasis, 43 breast cancer patients without bone metastasis, and 14 normal healthy
controls. The relationship between cell migration and proliferation and BST2 expression was also studied in a human breast
recombinant model system using migration and FACS analysis.
Results: The microarray demonstrated over expression of the BST2 gene in the bone metastatic breast cancer cell line (MDA-
231BO) compared to the primary human breast cancer cell line (MDA-231). The expression of the BST2 gene was significantly
increased in the bone metastatic breast cancer cell lines and tumor tissues compared to non-bone metastatic breast cancer cell
lines and tumor tissues by real time RT-PCR, Western blot and TMA. Furthermore, serum levels of BST2 measured by ELISA
were also significantly higher among patients with breast cancer metastatic to bone compared to breast cancer patients without
metastatic to bone (P < .0001). Most importantly, the breast cancer cell line that transfected with BST2 demonstrated increased
BST2 expressions, which was associated with increased cancer cell migration and cell proliferation.
Conclusion: These results provide novel data indicating the BST2 protein expression is associated with the formation of bone
metastases in human breast cancer. We believe that BST2 may be a potential biomarker in breast cancer with bone metastasis.
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Background
Breast cancer remains a major public health challenge in
the United States, with approximately 215,990 new cases
among women and 40,000 deaths projected for 2006 [1].
Bone metastasis is the most common complication of
breast cancer and skeletal involvement is present in 70%
of breast cancer autopsy cases [2]. Therefore, early detec-
tion of bone metastases will improve the quality of life
and decrease morbidity and mortality [1]. Studies are cur-
rently in progress to look at ways to prevent metastatic
breast cancer in women. Multiple literatures have
reported that abnormal elevation rates of biomarkers,
34.6% for carcinoembryonic antigen (CEA), 30.8% for
carbohydrate antigen 19-9 (CA19-9) and 30.8% for can-
cer antigen 125 (CA125) have been observed in cases of
bone metastasis [3]. However, there is no sensitive, spe-
cific and low-cost test to detect early bone metastases [4].
In order to discover a sensitive and specific biomarker for
detection of early bone metastases in breast cancer, we
have analyzed gene expressions of MDA-231BO, a bone
metastatic breast cancer cell line and compared it to MDA-
231, a non-bone metastatic breast cancer cell line by
cDNA microarray. In our present study, we present a novel
analysis of differential expressions of bone marrow stro-
mal protein 2 (BST2) in the breast cancer with bone
metastasis vs. breast cancer without bone metastasis.
The BST2 gene is also known as the HM1.24 antigen
located on chromosome 19p13.2 [5]. It is a transmem-
brane glycoprotein with a molecular weight of 35 kDa and
consists of 180 amino acids [6]. BST2 is expressed on
mature, normal and neoplastic B cells, but not on other
cells in the peripheral blood, bone marrow, liver, spleen,
and breast tissues of healthy individuals or patients with
plasma-cell malignancies [6]. The BST2 was previously
reported that it may be involved in pre-B cell growth via
cell-cell interaction by Dr Ohtomo [7]. The BST2 expres-
sion has been identified in multiple myeloma and
involved in the tumor invasion and progression [8,9].
Walter-Yohrling reported that higher levels of BST2 were
observed in metastatic ovarian cancer tissues than non-
metastatic ovarian cancer tissues [9]. In our present study,
we investigated the expression and the role of BST2 in the
initiation and development of bone metastatic breast can-
cer.
The process of bone metastasis is believed to occur in
three steps: "(1) proliferation and invasion of cancer cells
at a primary site, (2) intravasation, migration in the circu-
lation and extravasation of cancer cells, and (3) Specific
for bone metastases, the arrest of cancer cells in the bone
marrow, egress from central sinus, attachment to bone
surfaces, osteoclastic bone destruction, and colonization
in bone" [10,11]. BST2 is a 35-kDa membrane protein
characterized by a tandem repeat of three cis-elements in
the promoter region for a transcription factor, signal
transducer and activators of transcription 3 (STAT3),
which ultimately mediates the IL-6 response gene expres-
sion [12]. It is well-known that STAT3 and to some extent
STAT1 is activated in breast cancers and that constitutively
active mutants of STAT3 promote the growth and survival
of tumor cells thereby contributing to malignancy [13-
15]. STAT3 and STAT1 can be activated by various recep-
tors and non-receptor tyrosine kinases [14,16]. It is con-
ceivable that BST2 is an important regulator in the STAT3/
BST2/IL6 pathway leading to increased cell proliferation,
as well as osteoclastic bone destruction and/or production
in the bone metastatic breast cancer. In our present study,
we employed RNAi techniques to suppress the BST2
expression to investigate the effects of BST2 modulation




MDA-231, a non-bone metastatic breast cancer and MDA-
231BO, bone metastatic breast cancer cell lines for cDNA
microarray assay were obtained from Dr. Yoneda. Addi-
tionally, a normal breast cell line (MCF-10A) and six pri-
mary breast cancer cell lines (HTB-121, BC701,
UACC812, MCF-7, T47D and MDA-468) were purchased
from the American Type Culture Collection (ATCC, Inc).
The cell lines were maintained in Dulbecco's modified
Eagle's medium (DMEM) with L-glutamine supple-
mented with 10% fetal bovine serum, 50 units/ml Strep-
tomycin-penicillin, 1% non-essential amino acid, and
HPEBS. They were incubated at 37 degrees C with 5%
CO2. The RNAs, DNAs and proteins from all the cell lines
were isolated with Trizol (Life Technologies, Carlsbad,
CA) according to kit instructions.
cDNA Microarray analysis
A bone-seeking clone (MDA-231BO) of the human breast
cancer cell line MDA-231 was constructed by sequential
passages in mice and the metastatic cells collected from
bone [17]. The biological characteristics of MDA-231BO
were identified with higher occurrences in metastasis to
the bone compared with the MDA-231 parental cells
(MDA-231 cell line) [17]. In order to discover a sensitive
and specific biomarker for detection of early bone metas-
tases in breast cancer, we analyzed the differential gene
expressions of MDA-231BO, a bone metastatic breast can-
cer cell line and compared it to MDA-231, a non-bone
metastatic breast cancer cell line. The total RNA was
extracted from MDA-231BO and MDA-231 cell lines, as
previously described [18]. The total RNA (100 ug) was
used to produce labeled cDNA by anchored oligo (dT)-
primer reverse transcription using SuperScript II reverse
transcriptase (Life Technologies, Inc, Carlsbad, CA) in the
presence of fluorescent dye, Cy5-dUTP or Cy3-dUTP
(Amersham, Piscataway, NJ), respectively. The robot in
the cDNA microarray facility at the Albert Einstein CollegeBMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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of Medicine (AECOM) has the precision to spot 9568 PCR
products onto a single glass slide. From Genome Systems,
we have obtained 9568 unique human cDNAs from the
I.M.A.G.E. consortium that represent 15–20% of all
human genes [19] (AECOM website: http://
microarray1k.aecom.yu.edu). The fluorescent cDNA
probes were then hybridized to Silane glass slides with
9568 cDNA human gene spots were hybridized according
to AECOM standard protocol in which each slide was
probed with bone metastatic breast cancer and non-bone
metastatic breast cancer. Slides were scanned in our
microarray facility scanner. Data from the hybridization
reactions are collected using a two-colored laser scanning
confocal microscope that is custom designed and built at
AECOM specifically for maximum sensitivity necessary to
measure low abundance mRNAs. The images were
exported to the GenePix Pro 3.0 software (Axon Instru-
ments, Inc, Union City, CA) for signal intensity analysis.
Poor-quality spots were flagged and excluded from analy-
sis. Signal intensity information was exported to Excel.
The data was normalized for statistical analysis. Locally
weighted linear regression (LOWESS) analysis is a widely
used normalization method to reduce systematic errors in
the measured expression levels. Normalization algo-
rithms can be applied either globally (to the entire data
set) or locally (to some physical subset of the data) by
GenePix software. The output file of normalized data can
be saved directly to your hard drive, and can be used as the
input file for the "Filtering" module. The "Normalization"
module also generates a graphical file containing data
plots of Ratio vs. Geometrical Mean of R&G Intensity
(before and after normalization). This module performs
data filtering by eliminating bad/absent flag spots and
weak signals (lower than "A" cutoff). The input file was
the result file from the "Normalization" module. The out-
put file can be saved directly to your hard drive, and can
be used as an input file for the "Comparison" module.
This module performs Ratio filtering. For one dataset
(chip), this module performs Ratio filtering (Up & Down
regulated genes). When comparing multiple datasets, the
Ratio filtering test must be satisfied in all datasets for a
given gene to be selected. Testing is satisfied by expression
ratios in either the same or opposite direction. The input
file was the result file from the "Filtering" module. Data
were sorted based on "fold change," and genes with at
least 1.5-fold up-regulation or down-regulation were
accepted as significant alteration and the genes have a sig-
nificant differential expression in at least four of five
experiments chosen for further consideration.
Measurement of BST2 mRNA and protein expressions in 
breast cancer cell lines by Real time RT-PCR and Western 
Blot Assays
Total RNAs and proteins were isolated from each cell line
(MCF-10A, HTB-121, UACC812, MCF-7, T47D, MDA-
468, BC701, MDA-231 and MDA-231BO) as previously
described [18] and BST2 mRNA and protein expressions
determined by real time RT-PCR and Western blot assays.
Commercial BST2-P polyoclonal antibody against BST2
was optimized for Western blot assay (FabGennix Inc,
Texas). For each sample, the expression of the BST2 gene
and the β-actin loading control was determined. The ratio
of the target-to-β-actin was calculated as the normalized
value. The real time PCR and Western blot were repeated
three times.
Delineation of BST2 expression in human breast cancer 
tissueusing Tissue Microarray-Immunohisochemistry 
(TMA-IHC)
BST2 expression in human breast tissue specimens (nor-
mal breast, non-bone metastatic breast cancer and bone
metastatic breast cancer tissues) was assessed using TMAs
stained with BST2 antibody. Commercial BST2-P polyo-
clonal antibody against BST2 was optimized for TMA-IHC
assay (FabGennix Inc, Texas, USA). TMAs were purchased
from MTR Scientific (MTR Scientific Inc, MD) and were
comprised of 116 tissue cores from 50 breast tumors (30
non-bone metastatic and 20 bone metastatic breast
tumors) and 8 normal breast samples. These 20 speci-
mens were from the bone metastasis group of the patients
with bone metastasis only. Breast cancer tissues were col-
lected from 50 breast cancer patients with and without
clinical and bone scan evidences of bone metastases prior
to treatment. The bone metastasis and non-bone metasta-
sis were identified by bone scan examination. The slides
were de-paraffinized with xylene and rehydrated with
decreasing concentrations of alcohol and water. Heat-
induced epitope retrieval was performed by placing slides
in plastic coplin jars and a citrate buffer (pH 6.0; Bio-
Genex, Sandown, NH) using a decloaking chamber (Bio-
care Medical, Walnut Creek, CA) for 30 minutes. After
heat-induced epitope retrieval, endogenous peroxidase
was blocked with 0.3% H2O2 in PBS for 20 minutes, fol-
lowed by washing twice in PBS and then incubated for 30
minutes with biotinylated secondary antibodies (Vector
Laboratories) diluted to 1:250 with universal blocking
reagent and then incubated for 45 minutes with an avidin-
biotin complex method reagent (Vectastain Elite ABC kit;
Vector Laboratories). After development, slides were
washed twice with distilled water, lightly counterstained
with Mayer's hematoxylin, dehydrated, cleared, and
mounted with resinous mounting medium. This protocol
has been approved by the IRB of Affiliated Guangzhou
First People's Hospital, Guangzhou Medical College, and
AECOM. Analysis of TMA-IHC included the following: A
quantitative analysis of the immune reactive sections
related to the total tissue area was performed. We meas-
ured the percentage of positive immune reactivity using a
mouse anti-human BST2 Ab in the tissue epithelium (nor-
mal and tumor). The histological images were capturedBMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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with an OLYMPUS BX50 system microscope (Olympus
Microscopes, Tokyo, Japan) with an objective magnifica-
tion of 20×, through a video camera (Sony, Tokyo, Japan)
and digitized with Image-Pro Plus for Windows software.
In each slide, 300 cells per core were measured.
Delineation of BST2 serum levels in breast cancer cases by 
enzyme-linked immunoabsorbent assay (ELISA)
The peripheral serums were collected from 86 breast can-
cer patients with and without clinical and bone scan evi-
dences of bone metastases prior to treatment. The bone
metastasis and non-bone metastasis were identified by
bone scan examination. BST2 expressions was measured
in the serum from 14 normal healthy individuals, 43 non-
bone metastatic breast cancer and 43 bone metastatic
breast cancer cases using ELISA as per our standard proto-
col. The BST2-Fc antibody in 1 μg/ml PBS was added to
96-well plates respectively, and incubated for 1 hour at
37°C with serum samples. Reactivity was measured by
absorbance at 450 nm. Resulting antigen levels were pre-
sented as a mean difference from OD at 450 nm of mAb
coated wells. OD obtained without serum was subtracted
from mean OD of the sample wells. The ELISA experiment
was repeated three times. This protocol for human sam-
ples has been approved by the IRB.
Effects of BST2 on migration of breast cancer cells were 
analyzed by migration assay
The migration assay was measured using Transwell (Cos-
tar, NY, pore size, 8-μm) in 24-well dishes. Before per-
forming the migration assay, 0.5 and 3 μg of pcDNA3-
BST2 or pcDNA3-empty vector was transfected into 1 ×
106 MDA-231 cells, a human breast cancer cell line with
low metastasis (BST2 deficient), respectively, using the
PolyFect Transfection Reagent kit (Qiagen, CA). MDA-
231+pcDNA3-BST2 with BST2 proficiency and MDA-231+empty
vector with BST2 deficiency were suspended at 24 hours
post-transfection. Approximately 2 × 104 cells in a 100 μl
of RPLM-1640 medium without serum were placed in the
upper chamber. In the lower chamber, 200 μl of osteob-
last condition medium was placed. The plates were incu-
bated for 24 hours at 37°C in 5% CO2. Then, the cells
were fixed for 15 min in methanol and stained for 15 min
with 0.05% crystal violet. Cells were counted under
microscope. The expression level of BST2 protein also was
detected using Western blot assays. β-actin was used as a
loading control. Each clone was plated in triplicate in each
experiment, and each experiment was repeated at least
three times.
Fluorescence-activated cell sorting (FACS) analysis of cell 
cycle and apoptosis
Cell cycle distribution and apoptosis were analyzed in
MDA-231+pcDNA3-BST2 and MDA-231+empty vector breast can-
cer cell lines using a FACS apparatus (Becton-Dickinson,
KY). The cells were gathered at 24, 36 and 48 hours post-
transfection, washed with PBS, and centrifuged. Pellets
were fixed with ice-cold 70% ethanol for 1 hour at 4°C.
The cells were then centrifuged for 5 min, the pellets were
washed, re-suspended in PBS, and treated with RNase A at
5 μg/mL at 37°C for 30 minutes. The cells were chilled
over ice for 10 minutes and stained with Propidium
iodide at 50 μg/mL for 30 min at room temperature in
darkness. Subsequent analysis of cell-cycle distribution
and apoptosis were performed by FACS using the FACS-
can (Becton-Dickinson, KY). Each of these experiments
was repeated at least three times.
Results
Up-regulation of the BST2 gene in bone metastatic breast 
cancer cell line by cDNA microarray
The cDNA microarray was performed as described above,
comparing a bone metastatic breast cancer cell line (MDA-
231BO) to a non-bone metastatic breast cancer cell line
(MDA-231), which served as a reference. In all 5 cDNA
microarray experiments, 124 poor-quality spots were
flagged and excluded from our analysis. We identified 172
genes, including 20 expressed sequence tags (ESTs), with
significant differential expression in at least four of the
five experiments. From the structure and function of the
genes, we selected several of interest for further study. We
found BST2, an important bone marrow stromal protein,
to be significantly up-regulated in the bone metastatic
breast cancer cell line, MDA-231BO, compared to MDA-
231 (Expression ratios = 3.2, 4.5, 4.29, 3.97 and 4.9) (Fig-
ure 1).
Measurement of BST2 mRNA and protein expression in 
breast cancer cell lines by real time RT-PCR and Western 
Blot Assays
Microarray results were confirmed and expanded by real
time RT-PCR and Western blot analyses. The BST2 mRNA
was significantly increased (P < 0.01) in the bone meta-
static breast cancer cell lines, MDA-231BO compared to
the normal breast cell line, MCF-10A, and the non-bone
metastatic breast cancer cell lines, HTB-121, UACC812,
MCF-7, T47D, MDA-468, BC-701 and MDA-231 by real
time RT-PCR (Figure 2). The expression level of BST2 pro-
tein was also increased in bone metastatic breast cancer
cell line, MB-231BO compared to the normal breast cell
line, MCF-10A and non-bone metastatic breast cancer cell
lines, HTB-121, UACC812, MCF-7, T47D, MDA-468, BC-
701 and MDA-231 by Western blot assay (Figure 3).
Delineation of BST2 expression in human breast cancer 
tissue using Tissue Microarray (TMA) 
Immunohisochemistry (IHC)
We characterized each of our 50 human breast tumor
samples (present on our TMA). The tumor sample was
classified as BST2 deficient as it was negatively stainedBMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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Treeview of differential gene expression data from bone metastatic breast cancer cell line, MDA-231BO vs. primary breast  cancer cell line, MDA-231) Figure 1
Treeview of differential gene expression data from bone metastatic breast cancer cell line, MDA-231BO vs. 
primary breast cancer cell line, MDA-231). Treeview demonstrates the differential gene profiles in the bone metastatic 
breast cancer cell line compared to primary breast cancer cell line. Up-regulation is indicated by red, down-regulation by green, 
and no significant change by dark. Figure 1 shows 50 genes with greatest differential expression in five cDNA microarray 
experiments.BMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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(absence of brown indicates reduced expression). We
observed that 1 out of 30 (3.3%) non-bone metastatic
breast cancer tissues and 11 out of 20 (55%) bone meta-
static breast cancer tissues showed increased BST2 expres-
sion, but none of the 8 (0.0%) normal breast tissues
displayed the increased expression (Figure 4). Applying
the one-tail Exact Fisher Test to this data, we obtained a p-
value < 0.0001. Our results indicated that the BST2 expres-
sion was significantly increased in the bone metastatic
breast cancer tissues.
Delineation of serum levels of BST2 in breast cancer cases 
byELISA
To assess the sensitivity in ELISA, two-fold serial dilutions
of recombinant BST2 proteins (1.25–120 pg/ml) were
used. We demonstrated that minimum detection limits
ranged from 1.25–5 pg/ml. Our result presented that the
mean absorption value + SD for normal healthy individu-
als, Non-bone metastatic Group, Bone metastatic Group
were 0.22 ± 0.05, 0.24 ± 0.11 and 0.51 ± 0.15, respectively
(Table 1). To evaluate the specificity of BST2 expression in
breast cancer with bone metastasis, 86 serum samples
from patients previously diagnosed with and without
bone metastasis by bone scan were determined by ELISA.
In all 43 BMBC cases, we demonstrated that 36 (84%) of
43 had increased serum levels of BST2 (BST2 > 0.26).
Real time RT-PCR demonstrates increased expression of BST2 mRNA in bone metastatic breast cancer cell line: MDA-231BO  compared to non-bone metastatic breast cancer cell lines: TB-121, UACC812, MCF-7, T47D, MDA-468, BC-701, MDA-231  and normal breast cell line: MCF-10A Figure 2
Real time RT-PCR demonstrates increased expression of BST2 mRNA in bone metastatic breast cancer cell 
line: MDA-231BO compared to non-bone metastatic breast cancer cell lines: TB-121, UACC812, MCF-7, 
T47D, MDA-468, BC-701, MDA-231 and normal breast cell line: MCF-10A. β-Actin was used to as a loading control.
Western blot demonstrates increased expression of the  BST2 protein in bone metastatic breast cancer cell line:  MDA-231BO compared to non-bone metastatic breast can- cer cell lines: TB-121, UACC812, MCF-7, T47D, MDA-468,  BC-701, MDA-231 and normal breast cell line: MCF-10A Figure 3
Western blot demonstrates increased expression of 
the BST2 protein in bone metastatic breast cancer 
cell line: MDA-231BO compared to non-bone meta-
static breast cancer cell lines: TB-121, UACC812, 
MCF-7, T47D, MDA-468, BC-701, MDA-231 and nor-
mal breast cell line: MCF-10A. β-Actin was used to as a 
loading control.BMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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Among the control group, 3 (7%) of 43 NBMBC patients
had increased serum levels of BST2 (BST2 > 0.26). Thus,
both sensitivity and specificity of this assay were 84% (36/
43) and 93% (40/43), respectively. Our results indicated
that breast cancer patients with bone metastasis exhibited
significantly increased serum BST2 as compared to breast
cancer patients without bone metastasis as well as normal
healthy individuals (p < .001) (Table 1).
Effect of BST2 on the migration ability of breast 
cancercells
The migration ability of BST2 on breast cancer cells was
analyzed using an in-vitro migration assay. The BST2
expression was induced into MDA-231, a human breast
cancer cell line with low BST2 expression (Figure 5A). At
48 hours post-transfection with BST2, the migration activ-
ities significantly increased in the pcDNA3-BST2-treated
BST2 deficient cell line (MDA-231) compared to the cells
treated with the empty vector (P < 0.01) (Figure 5B).
Effect of BST2 on cell proliferation of breast cancer cells
To determine whether the BST2 expression contributes to
cell proliferation and apoptosis profiles, we assessed cell
cycle and apoptosis profiles by FACS in a recombinant
BST2 cell model. At 24, 36 and 48 hours post-transfection
with BST2, the S-phase cell population significantly
increased in the pcDNA3-BST2-treated BST2 deficient cell
line (MDA-231) compared to the cells treated with the
empty vector (P < 0.01), (Figure 5C). However, the per-
centage of apoptotic cells was not significantly altered in
the pcDNA3-BST2-treated BST2 deficient cell line (MDA-
231) compared to the cells treated with the empty vector
(P > 0.05).
Discussion
Bone metastasis is one of the most common complica-
tions in patients with breast cancer. However, the precise
mechanism of metastatic bone disease in breast cancer
remains unknown. Recently, up-regulation of BST2
Table 1: Serum BST2 level in normal healthy individuals, non-bone metastatic and bone metastatic breast cancer cases
Serum levels
N > 0.26 Mean Dev Std Min Max
Normal Healthy Group 14 0 (0%) 0.22 0.05 009 0.26
Non-bone metastatic Group 43 3(7%) 0.24 0.11 0.17 0.52
Bone metastatic Group 43 36(84%)a 0.51b 0.15 0.22 0.81
a: P = 0.0006 (P < 0.001), b: P = 0.02 (P < 0.05)
This figure shows the BST2 expression in human breast cancer samples as determined by tissue array Figure 4
This figure shows the BST2 expression in human breast cancer samples as determined by tissue array. The 
bone metastatic breast cancer tissue (B) show the robust level of the BST2 expression, whereas the BST2 expression is absent 
in the non-bone metastatic breast cancer tissues (A). The brown staining in bone metastatic breast cancer cells demonstrates 
the significantly increased expression of BST2.BMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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A: Before performing the cell migration and proliferation assays, protein expression of BST2 were measured by Western blot  in MDA-231 cell line after transfection at 24, 36 and 48 hours with pcDNA3-BST2 (0.5 and 3 μg) and pcDNA3 empty vector  (0.5 and 3 μg), respectively Figure 5
A: Before performing the cell migration and proliferation assays, protein expression of BST2 were measured 
by Western blot in MDA-231 cell line after transfection at 24, 36 and 48 hours with pcDNA3-BST2 (0.5 and 3 
μg) and pcDNA3 empty vector (0.5 and 3 μg), respectively. Figure 5A shows that the BST2 protein expression is signif-
icantly increased by transfection with pcDNA3-BST2. β-Actin was used as a loading control. B: The graph shows that the 
migration activities of breast cancer cells (MDA-231) were measured at the 48-hour post-transfection with pcDNA3-BST2 (0.5 
and 3 μg) and pcDNA3 empty vector (0.5 and 3 μg), respectively. Figure 5B indicates significantly increased the pcDNA3-BST2-
treated cell line (MDA-231) compared to the cells treated with the empty vector (P < 0.01) (5B). C: The graph shows a FACS 
quantitative assessment of cells in the S phase of cell cycles in the MDA-231 cell line. Figure 5C represents the MDA-231 cell 
line at 24, 36 and 48-hour post-transfection with pcDNA3-BST2 (0.5 and 3 μg) and pcDNA3 empty vector (0.5 and 3 μg), 
respectively. The S-phase cell population significantly increased in the pcDNA3-BST2-treated cell line (MDA-231) compared to 
the cells treated with the empty vector (P < 0.01) (5C). These graphs show the mean values from three independent experi-
ments.BMC Cancer 2009, 9:102 http://www.biomedcentral.com/1471-2407/9/102
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mRNA was reported in endometrial cancer [20]. However,
the BST2 protein expressions aren't identified in the breast
cancer. In our current study, we have identified BST2, an
important bone marrow stromal cell growth factor, as sig-
nificantly up-regulated in a BMBC, compared to a NBMBC
by cDNA microarray (Figure 1). These results were further
confirmed in a large number of breast cancer cell lines
using real time RT-PCR and Western-blot assays (Figure 2
and 3). In a subsequent study, we expanded our investiga-
tion of BST2 expressions in human bone metastatic breast
cancer and non-bone metastatic breast cancer using TMA-
IHC. We demonstrated that the BST2 expression was sig-
nificantly increased in human bone metastatic breast can-
cer tissues compared to human non-bone metastatic
breast cancer and normal breast tissues by TMA (Figure 4).
This important finding supports our initial cell-line-based
results. In order to discover a novel, simple and sensitive
biomarker in bone metastatic breast cancer, we also meas-
ured serum BST2 level using ELISA. Thirty-six (84%) of 43
breast cancer patients with bone metastasis had signifi-
cantly increased serum levels of BST2 as indicated by
ELISA (Table 1). Among the control group, 3 (7%) of 43
breast cancer patient without bone metastasis had signifi-
cantly increased serum levels of BST2. The breast cancer
patients with bone metastasis exhibited significantly
increased serum BST2 as compared to breast cancer
patients without bone metastasis and normal healthy
individuals (p < .0001) (Table 1). These results indicated
that a novel biomarker, BST2, is up-regulated in breast
cancer cells with bone metastasis compared to in-breast
cancer cells without bone metastasis.
Cell proliferation, migration and invasion of cancer cells
at a primary site is an important step in the process of
bone metastasis [10]. In this study, we determined the
migration activities of breast cancer cells by an in-vitro
migration assay. We induced BST2 expressions in a breast
cancer cell line (MDA-231). Our results showed that the
migration activities were significantly increased in the
MDA-231 cells with high BST2 expression compared to
the MDA-231 cells with low BST2 expression (P < 0.01)
(Figure 5B). Additionally, we further assessed the role of
BST2 expression in the regulation of cell cycles progres-
sion and apoptosis in breast cancer cells, and we induced
BST2 expressions in a breast cancer cell line, MDA-231.
Subsequent FACS analysis indicated increased S-phase
fractions following induction of BST2 expressions (Figure
5C). We reassessed apoptosis activities in the MDA-231
cell line post-BST2 induction and observed insignificant
alteration in apoptosis by FACS. The results suggest that
the variable BST2 expression contributes to the alteration
of cell cycle kinetics in human breast cells. BST2 is a 35-
kDa membrane protein characterized by a tandem repeat
of three cis-elements in the promoter region for a tran-
scription factor, signal transducer and activators of tran-
scription 3 (STAT3), which ultimately mediates the IL-6
response gene expression [12]. It is well-known that
STAT3 and to some extent STAT1 is activated in breast can-
cers and that constitutively active mutants of STAT3 pro-
motes the growth and survival of tumor cells thereby
contributing to malignancy [13-15]. STAT3 and STAT1
can be activated by various receptor and non-receptor
tyrosine kinases [14,16]. Interleukin-6 (LI-6) is an impor-
tant growth and survival factor by the regulation of phos-
phatidylinositol 3-kinase signaling pathway in the
initiation and progression of human cancers [21]. It is
conceivable that BST2 may be an important regulator in
the STAT3/BST2/IL6 pathway leading to increased cell
migration and proliferation in the bone metastatic breast
cancer.
Conclusion
We conclude that we have demonstrated that the BST2
expression is significantly increased in bone metastatic
breast cancer. We believe that BST2 may be a potential
biomarker in bone metastatic breast cancer. We hope to
show that it will provide a convenient and sensitive diag-
nostic method for breast cancer patients with bone metas-
tasis and facilitate the development of novel diagnostic
and therapeutic interventions designed to prevent bone
metastases in breast cancer.
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